Karakulova Y V, Selyanina N V, Zhelnin A V, Filimonova T A, Cepilov S V
Vagner Perm State Medical University, Perm, Russia.
Perm Krai 'Perm Regional Clinical Hospital', Perm, Russia.
Zh Nevrol Psikhiatr Im S S Korsakova. 2016;116(8):36-39. doi: 10.17116/jnevro20161168136-39.
The aim of the research was to study the effect of the inclusion in the scheme cytoflavin patient care during the recovery period of ischemic stroke in the neuropsychological changes in the status and content of neurotrophins in serum. For this purpose we surveyed 52 patients who underwent a first ischemic stroke (29 women and 23 men) aged 52-74 years. Patients were divided into 2 groups: primary (25 patients) received in addition to basic therapy cytoflavin: intravenously at 20 ml per 400 ml of 5% glucose solution, 1 time a day for 10 days, then into 2 tablets 2 times a day for half an hour before food for a month, and the comparison group (27 patients) who received standard treatment. The control group consisted of 12 healthy people. In addition to standard clinical and laboratory tests were carried out a comprehensive neuropsychological study and evaluation of the data on the scale NIHSS, Bartell, Beck, Spielberger-Hanin, test «frontal dysfunction of the battery» and the Mini-Mental State Examination. Furthermore, determination carried neurotrophic factors: nerve growth factor (NGF) and brain-derived neurotrophic factor brain (BDNF). The study was conducted in the dynamics: before treatment and 2 months after treatment. Patients in the recovery period of the first ischemic stroke revealed moderate manifestations of neuropsychological disorders status and reduction of neurotrophic factors. Inclusion in cytoflavin scheme increased the efficiency of the treatment, which was manifested in a more pronounced when compared with the results of basic therapy, positive dynamics of neurological symptoms and improved cognitive function, accompanied by an increase in BDNF levels. The data on the efficacy and safety allow us to recommend its inclusion in the scheme of treatment of patients in the recovery period after the first carotid ischemic stroke.
该研究的目的是探讨在缺血性中风恢复期将细胞色素C纳入患者护理方案对血清中神经营养因子状态和含量的神经心理学变化的影响。为此，我们对52例首次发生缺血性中风的患者（29名女性和23名男性）进行了调查，年龄在52 - 74岁之间。患者分为2组：主要组（25例患者）除基础治疗外还接受细胞色素C：以每400毫升5%葡萄糖溶液20毫升静脉注射，每天1次，共10天，然后每天2次，每次2片，饭前半小时服用，持续1个月；对照组（27例患者）接受标准治疗。对照组由12名健康人组成。除标准临床和实验室检查外，还进行了全面的神经心理学研究，并根据NIHSS量表、Bartell量表、Beck量表、Spielberger - Hanin量表、“额叶功能障碍组合测试”和简易精神状态检查表对数据进行评估。此外，还测定了神经营养因子：神经生长因子（NGF）和脑源性神经营养因子（BDNF）。研究在治疗前和治疗后2个月进行动态观察。首次缺血性中风恢复期的患者表现出神经心理学障碍状态的中度表现和神经营养因子的减少。将细胞色素C纳入治疗方案提高了治疗效果，与基础治疗结果相比，其表现为神经症状更明显的积极动态变化和认知功能改善，同时BDNF水平升高。关于疗效和安全性的数据使我们建议将其纳入首次颈动脉缺血性中风恢复期患者的治疗方案。
